| Name | Title | Contact Details |
|---|
Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China; Boston and San Diego, USA.
Epicentre Technologies Corp is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need.
Medicilon Inc. is a prominent Contract Research Organization (CRO) based in Shanghai, China, established in 2004. The company specializes in comprehensive preclinical drug discovery and development services, helping pharmaceutical and biotech clients progress from concept to Investigational New Drug (IND) filing. With over 300,000 square feet of lab space and a team of more than 2,400 scientists, Medicilon is recognized for its expertise and innovation in the field. The company offers a wide range of services, including drug discovery, CMC development, and preclinical research. Their capabilities encompass precision chemical synthesis, GMP-compliant API manufacturing, and extensive pharmacology and toxicology studies. Medicilon adheres to FDA methodologies and international standards, ensuring regulatory compliance throughout the development process. With a focus on client-centric solutions, Medicilon has successfully conducted over 10,000 studies and serves more than 2,000 clients worldwide, emphasizing long-term partnerships and support for drug development programs.
We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.